Press Releases April 5, 2026 08:00 PM

Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference

Neumora Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
NMRA

Neumora Therapeutics, a clinical-stage biopharmaceutical company specializing in novel neuroscience therapies, announced its participation in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, with a live webcast available to investors and the public.

Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
NMRA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Neumora specializes in developing novel therapeutics for brain diseases targeting underserved and prevalent conditions.
  • The company will engage investors and stakeholders through a fireside chat at a prominent healthcare conference, outlining its clinical pipeline and strategy.
  • Neumora aims to revolutionize neuroscience drug development to improve treatment outcomes and the quality of life for patients.

WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 10:15 a.m. ET.

A live webcast of the fireside chat will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.

About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.

Neumora Contact:
Helen Rubinstein
617-402-5700
[email protected]


Risks

  • As a clinical-stage biopharmaceutical company, Neumora faces inherent risks including clinical trial outcomes and regulatory approvals impacting its pipeline progress.
  • The company operates in the highly competitive and volatile biotech sector, where innovation timelines and funding conditions can significantly affect valuation.
  • Market reception to their novel treatment approaches is uncertain and dependent on successful development and commercialization efforts.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026